Advertisement

Tumor Biology

, Volume 35, Issue 1, pp 475–481 | Cite as

Association between myeloperoxidase G-463A polymorphism and lung cancer risk

  • Chao Huang
  • Lu Ma
  • Dejia Li
Research Article

Abstract

Many epidemiologic studies have investigated the association between myeloperoxidase (MPO) G-463A polymorphism and lung cancer risk, but the results were controversial. We performed a meta-analysis of 25 studies on MPO polymorphism and lung cancer risk published before July 2013. The allele of A was found to be associated with decreased risk of lung cancer compared with G allele (OR, 0.90; 95 % CI, 0.82–0.98) in the general population. The significant association remained in the comparison between AA + AG and GG (OR, 0.92; 95 % CI, 0.87–0.98). When it was stratified according to Asian population, the association between MPO polymorphism and lung cancer risk was further strengthened. However, no associations were found in the Caucasian population. This meta-analysis has demonstrated that MPO polymorphism might contribute to individual’s susceptibility to lung cancer in Asian population. Caucasian authors could re-investigate the association between MPO polymorphism and lung cancer risk with more specific participants. Future studies focusing on interactions between combined genes and environmental risk factors are warranted.

Keywords

Myeloperoxidase Polymorphism Lung cancer Meta-analysis 

Notes

Conflicts of interest

None

References

  1. 1.
    Lee PN. Relation between exposure to asbestos and smoking jointly and the risk of lung cancer. Occup Environ Med. 2001;58:145–53.PubMedCrossRefGoogle Scholar
  2. 2.
    Alberg AJ, Ford JG, Samet JM, American College of Chest Physicians. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest. 2007;132:29S–55S.PubMedCrossRefGoogle Scholar
  3. 3.
    Marshall AL, Christiani DC. Genetic susceptibility to lung cancer—light at the end of the tunnel? Carcinogenesis. 2013;34:487–502.PubMedCrossRefGoogle Scholar
  4. 4.
    Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol. 2005;77:598–625.PubMedCrossRefGoogle Scholar
  5. 5.
    Cascorbi I, Henning S, Brockmoller J, Gephart J, Meisel C, Muller JM, et al. Substantially reduced risk of cancer of the aerodigestive tract in subjects with variant—463a of the myeloperoxidase gene. Cancer Res. 2000;60:644–9.PubMedGoogle Scholar
  6. 6.
    Kiyohara C, Yoshimasu K, Takayama K, Nakanishi Y. Nqo1, mpo, and the risk of lung cancer: a huge review. Genet Med. 2005;7:463–78.PubMedCrossRefGoogle Scholar
  7. 7.
    Taioli E, Benhamou S, Bouchardy C, Cascorbi I, Cajas-Salazar N, Dally H, et al. Myeloperoxidase g-463a polymorphism and lung cancer: a huge genetic susceptibility to environmental carcinogens pooled analysis. Genet Med. 2007;9:67–73.PubMedCrossRefGoogle Scholar
  8. 8.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.PubMedCrossRefGoogle Scholar
  9. 9.
    Lu W, Xing D, Qi J, Tan W, Miao X, Lin D. Genetic polymorphism in myeloperoxidase but not gstm1 is associated with risk of lung squamous cell carcinoma in a Chinese population. Int J Cancer. 2002;102:275–9.PubMedCrossRefGoogle Scholar
  10. 10.
    Wu XM, Zhou YK, Ren S. Hao QL: [gene polymorphism of myeloperoxidase and genetic susceptibility to lung cancer]. Ai Zheng. 2003;22:912–5.PubMedGoogle Scholar
  11. 11.
    Chan EC, Lam SY, Fu KH, Kwong YL. Polymorphisms of the gstm1, gstp1, mpo, xrcc1, and nqo1 genes in Chinese patients with non-small cell lung cancers: relationship with aberrant promoter methylation of the cdkn2a and rarb genes. Cancer Genet Cytogenet. 2005;162:10–20.PubMedCrossRefGoogle Scholar
  12. 12.
    Park JH, Park JM, Kim EJ, Cha SI, Lee EB, Kim CH, et al. Myeloperoxidase-463g > a polymorphism and risk of primary lung cancer in a Korean population. Cancer Detect Prev. 2006;30:257–61.PubMedCrossRefGoogle Scholar
  13. 13.
    Zhang T, Hong X, Wu Y, Wu Y. Myeloperoxidase polymorphism in lung cancer patients of Henan Han population. Journal of Zhengzhou University. 2007;42:448–50.Google Scholar
  14. 14.
    Yang M, Choi Y, Hwangbo B, Lee JS. Combined effects of genetic polymorphisms in six selected genes on lung cancer susceptibility. Lung Cancer. 2007;57:135–42.PubMedCrossRefGoogle Scholar
  15. 15.
    Yoon KA, Kim JH, Gil HJ, Hwang H, Hwangbo B, Lee JS. Cyp1b1, cyp1a1, mpo, and gstp1 polymorphisms and lung cancer risk in never-smoking korean women. Lung Cancer. 2008;60:40–6.PubMedCrossRefGoogle Scholar
  16. 16.
    Schabath MB, Spitz MR, Zhang X, Delclos GL, Wu X. Genetic variants of myeloperoxidase and lung cancer risk. Carcinogenesis. 2000;21:1163–6.PubMedCrossRefGoogle Scholar
  17. 17.
    Xu LL, Liu G, Miller DP, Zhou W, Lynch TJ, Wain JC, et al. Counterpoint: the myeloperoxidase-463g—a polymorphism does not decrease lung cancer susceptibility in Caucasians. Cancer Epidemiol Biomarkers Prev. 2002;11:1555–9.PubMedGoogle Scholar
  18. 18.
    Feyler A, Voho A, Bouchardy C, Kuokkanen K, Dayer P, Hirvonen A, et al. Point: myeloperoxidase-463g—a polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11:1550–4.PubMedGoogle Scholar
  19. 19.
    Dally H, Gassner K, Jager B, Schmezer P, Spiegelhalder B, Edler L, et al. Myeloperoxidase (mpo) genotype and lung cancer histologic types: the mpo-463 a allele is associated with reduced risk for small cell lung cancer in smokers. Int J Cancer. 2002;102:530–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Schabath MB, Spitz MR, Delclos GL, Gunn GB, Whitehead LW, Wu X. Association between asbestos exposure, cigarette smoking, myeloperoxidase (mpo) genotypes, and lung cancer risk. Am J Ind Med. 2002;42:29–37.PubMedCrossRefGoogle Scholar
  21. 21.
    Kantarci OH, Lesnick TG, Yang P, Meyer RL, Hebrink DD, McMurray CT, et al. Myeloperoxidase-463 (g–a) polymorphism associated with lower risk of lung cancer. Mayo Clin Proc. 2002;77:17–22.PubMedCrossRefGoogle Scholar
  22. 22.
    Misra RR, Tangrea JA, Virtamo J, Ratnasinghe D, Andersen MR, Barrett M, et al. Variation in the promoter region of the myeloperoxidase gene is not directly related to lung cancer risk among male smokers in Finland. Cancer Lett. 2001;164:161–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Chevrier I, Stucker I, Houllier AM, Cenee S, Beaune P, Laurent-Puig P, et al. Myeloperoxidase: new polymorphisms and relation with lung cancer risk. Pharmacogenetics. 2003;13:729–39.PubMedCrossRefGoogle Scholar
  24. 24.
    Cajas-Salazar N, Sierra-Torres CH, Salama SA, Zwischenberger JB, Au WW. Combined effect of mpo, gstm1 and gstt1 polymorphisms on chromosome aberrations and lung cancer risk. Int J Hyg Environ Health. 2003;206:473–83.PubMedCrossRefGoogle Scholar
  25. 25.
    Liu G, Zhou W, Wang LI, Park S, Miller DP, Xu LL, et al. Mpo and sod2 polymorphisms, gender, and the risk of non-small cell lung carcinoma. Cancer Lett. 2004;214:69–79.PubMedCrossRefGoogle Scholar
  26. 26.
    Harms C, Salama SA, Sierra-Torres CH, Cajas-Salazar N, Au WW. Polymorphisms in DNA repair genes, chromosome aberrations, and lung cancer. Environ Mol Mutagen. 2004;44:74–82.PubMedCrossRefGoogle Scholar
  27. 27.
    Larsen JE, Colosimo ML, Yang IA, Bowman R, Zimmerman PV, Fong KM. Cyp1a1 ile462val and mpo g-463a interact to increase risk of adenocarcinoma but not squamous cell carcinoma of the lung. Carcinogenesis. 2006;27:525–32.PubMedCrossRefGoogle Scholar
  28. 28.
    Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, Stangeland LB, et al. A comprehensive analysis of phase i and phase ii metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers. Carcinogenesis. 2008;29:1164–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Rotunno M, Yu K, Lubin JH, Consonni D, Pesatori AC, Goldstein AM, et al. Phase i metabolic genes and risk of lung cancer: multiple polymorphisms and mrna expression. PLoS One. 2009;4:e5652.PubMedCentralPubMedCrossRefGoogle Scholar
  30. 30.
    Arslan S, Pinarbasi H, Silig Y. Myeloperoxidase g-463a polymorphism and risk of lung and prostate cancer in a Turkish population. Mol Med Rep. 2011;4:87–92.PubMedGoogle Scholar
  31. 31.
    London SJ, Lehman TA, Taylor JA. Myeloperoxidase genetic polymorphism and lung cancer risk. Cancer Res. 1997;57:5001–3.PubMedGoogle Scholar
  32. 32.
    Le Marchand L, Seifried A, Lum A, Wilkens LR. Association of the myeloperoxidase -463g–a polymorphism with lung cancer risk. Cancer Epidemiol Biomarkers Prev. 2000;9:181–4.PubMedGoogle Scholar
  33. 33.
    Mattson ME, Pollack ES, Cullen JW. What are the odds that smoking will kill you? Am J Public Health. 1987;77:425–31.PubMedCrossRefGoogle Scholar
  34. 34.
    Peto R, Darby S, Deo H, Silcocks P, Whitley E, Doll R. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case–control studies. BMJ. 2000;321:323–9.PubMedCrossRefGoogle Scholar
  35. 35.
    Doll R, Peto R. The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J Natl Cancer Inst. 1981;66:1191–308.PubMedGoogle Scholar
  36. 36.
    Schwartz AG, Prysak GM, Bock CH, Cote ML. The molecular epidemiology of lung cancer. Carcinogenesis. 2007;28:507–18.PubMedCrossRefGoogle Scholar
  37. 37.
    Landi MT, Chatterjee N, Yu K, Goldin LR, Goldstein AM, Rotunno M, et al. A genome-wide association study of lung cancer identifies a region of chromosome 5p15 associated with risk for adenocarcinoma. Am J Hum Genet. 2009;85:679–91.PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Ito H, McKay JD, Hosono S, Hida T, Yatabe Y, Mitsudomi T, et al. Association between a genome-wide association study-identified locus and the risk of lung cancer in Japanese population. J Thorac Oncol. 2012;7:790–8.PubMedCrossRefGoogle Scholar
  39. 39.
    de Mello RA, Ferreira M, Costa S, Costa BM, Pires FS, Neves I, et al. Association between egf +61 genetic polymorphisms and non-small cell lung cancer increased risk in a Portuguese population: a case–control study. Tumour Biol. 2012;33:1341–8.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  1. 1.Global Health Institute, School of Public HealthWuhan UniversityWuhanChina

Personalised recommendations